株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヒトインスリンの世界市場:2015年〜2019年

Global Human Insulin Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 247841
出版日 ページ情報 英文 63 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
ヒトインスリンの世界市場:2015年〜2019年 Global Human Insulin Market 2015-2019
出版日: 2015年08月12日 ページ情報: 英文 63 Pages
概要

世界のヒトインスリン市場は、2014年〜2019年のCAGRで、10.29%の成長が見込まれています。

当レポートでは、世界のヒトインスリン市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

  • ハイライト

第2章 調査範囲

  • 市場概要
  • 主要ベンダーの製品

第3章 製品プロファイル

第4章 市場調査手法

  • 調査手法
  • 経済指標

第5章 疾患の概要

  • 疫学

第6章 パイプライン分析

第7章 イントロダクション

第8章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第9章 市場区分:インスリンの種類別

  • 即効性
  • 中時間作用性
  • 長時間作用性

第10章 市場区分:疾患の種類別

第11章 地域区分

第12章 市場成長促進要因

第13章 成長促進要因の影響

第14章 市場の課題

第15章 促進要因と課題の影響

第16章 市場動向

第17章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第18章 主要ベンダー分析

  • Lilly
  • Novo Nordisk
  • Sanofi

第19章 付録

  • 略語リスト

第20章 Technavioについて

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR6990

About diabetes

Insulin is a hormone produced by beta cells of the pancreas that plays a key role in the regulation of blood glucose levels. It controls the body systems and regulates the uptake of amino acids by body cells. It helps cells absorb glucose from the blood. In diabetics, cells stop responding to the insulin produced. As a result, glucose in the blood cannot be absorbed by the cells of the body. This condition damages body tissues over the period of time and causes disabling and life-threatening health complications such as diabetic nephropathy and diabetic retinopathy. In type 1 diabetes, the body does not produces sufficient insulin to regulate blood glucose level. Individuals with this type of diabetes need to take insulin daily. Patients with type 2 diabetes also need doses of insulin coupled with medication. Different types of insulin such as human insulin and insulin analogs are available as insulin replacement therapy.

Technavio's analysts forecast the global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes.

Technavio's report, Global Human Insulin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report includes a discussion of the key vendors operating in this market.

Key vendors

  • Eli Lilly
  • Novo Nordisk
  • Sanofi

Other Prominent Vendors

  • Biocon
  • Biodel
  • Biogenomics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Diamyd Medical
  • Diasome Pharmaceuticals
  • DiaVacs
  • Pfizer
  • Generex Biotechnology
  • Lexicon Pharmaceuticals
  • Macrogenics
  • Merck
  • Oramed Pharmaceuticals
  • Osiris Therapeutics
  • Thermalin Diabetes
  • Tolerion
  • Wockhardt
  • XOMA Corporation

Market driver

  • Increase in prevalence of diabetes
  • For a full, detailed list, view our report

Market challenge

  • Stringent regulatory environment
  • For a full, detailed list, view our report

Market trend

  • Increasing R&D for novel mechanisms
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Product profiles

PART 04: Market research methodology

  • Research methodology
  • Economic indicators

PART 05: Disease overview

  • Epidemiology

PART 06: Pipeline analysis

PART 07: Introduction

  • Key market highlights

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by type of insulin

  • Fast-acting insulin
  • Intermediate-acting insulin
  • Long-acting insulin

PART 10: Market segmentation by type of disease

PART 11: Geographical segmentation

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 18: Key vendor analysis

  • Lilly
  • Novo Nordisk
  • Sanofi

PART 19: Appendix

  • List of abbreviation

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Diabetes prevalence rate in various countries (2000 and 2030)
  • Exhibit 03: Global human insulin market 2014-2019 ($ Billions)
  • Exhibit 04: Five forces analysis
  • Exhibit 05: Global human insulin market by type of disease 2014
  • Exhibit 07: Global human insulin market segmentation by geography 2014
  • Exhibit 08: Impact of drivers
  • Exhibit 09: Impact of drivers and challenges
  • Exhibit 10: Novo Nordisk: Company strategy
  • Exhibit 11: Modern insulins: Drug sales 2010-2014 ($ millions)
  • Exhibit 12: NovoRapid/NovoLog: Drug sales 2010-2014 ($ millions)
  • Exhibit 13: Levemir: Drug sales 2010-2014 ($ millions)
  • Exhibit 14: NovoMix: Drug sales 2010-2014 ($ millions)
  • Exhibit 15: Human insulins: Drug sales 2010-2014 ($ millions)
  • Exhibit 16: Sanofi: Company strategy
  • Exhibit 17: Lantus: Drug sales 2010-2014 ($ millions)
  • Exhibit 18: Apidra: Drug sales 2010-2014 ($ millions)
  • Exhibit 19: Insuman: Drug sales 2010-2014 ($ millions)
  • Exhibit 20: Lilly: Company strategy
  • Exhibit 21: Humalog: Drug sales 2010-2014 ($ millions)
  • Exhibit 22: Humulin: Drug sales 2010-2014 ($ millions)
  • Exhibit 23: Novo Nordisk: R&D expenditure 2014
Back to Top